RT Journal Article
T1 EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.
A1 Serrano, Maria J
A1 Ortega, Francisco G
A1 Alvarez-Cubero, Maria J
A1 Nadal, Rosa
A1 Sanchez-Rovira, Pedro
A1 Salido, Marta
A1 Rodríguez, María
A1 García-Puche, Jose L
A1 Delgado-Rodriguez, Miguel
A1 Solé, Francisco
A1 García, Maria A
A1 Perán, Macarena
A1 Rosell, Rafael
A1 Marchal, Juan A
A1 Lorente, Jose A
K1 Breast Cancer
K1 Circulating Tumor Cells
K1 EGFR
K1 Epithelial-Mesenchymal Transition
K1 Vimentin
K1 Slug
K1 Bcl-2
K1 Apoptosis
K1 Neoplasias de la mama
K1 Transición epitelial-mesenquimal
K1 Gastrópodos
K1 Animales
K1 Filamentos intermedios
K1 Queratinas
K1 Línea celular tumoral
K1 Modelos teóricos
K1 Células neoplásicas circulantes
K1 Fenotipo
K1 Pronóstico
K1 Marcadores biológicos de tumor
K1 Humanos
K1 Vimentina
AB Circulating tumor cells (CTCs) are frequently associated with epithelial-mesenchymal transition (EMT).The objective of this study was to detect EMT phenotype through Vimentin (VIM) and Slug expression in cytokeratin (CK)-negative CTCs in non-metastatic breast cancer patients and to determine the importance of EGFR in the EMT phenomenon. In CK-negative CTCs samples, both VIM and Slug markers were co-expressed in the most of patients. Among patients EGFR+, half of them were positive for these EMT markers. Furthermore, after a systemic treatment 68% of patients switched from CK- to CK+ CTCs. In our experimental model we found that activation of EGFR signaling by its ligand on MCF-7 cells is sufficient to increase EMT phenotypes, to inhibit apoptotic events and to induce the loss of CK expression. The simultaneous detection of both EGFR and EMT markers in CTCs may improve prognostic or predictive information in patients with operable breast cancer.
PB Impact Journals
YR 2014
FD 2014-09-15
LK http://hdl.handle.net/10668/2183
UL http://hdl.handle.net/10668/2183
LA en
NO Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M, et al. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget. 2014                         ; 5(17):7486-97
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 12, 2025